[go: up one dir, main page]

MX392945B - Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. - Google Patents

Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.

Info

Publication number
MX392945B
MX392945B MX2019013537A MX2019013537A MX392945B MX 392945 B MX392945 B MX 392945B MX 2019013537 A MX2019013537 A MX 2019013537A MX 2019013537 A MX2019013537 A MX 2019013537A MX 392945 B MX392945 B MX 392945B
Authority
MX
Mexico
Prior art keywords
compounds
diseases
prevention
treatment
aspects
Prior art date
Application number
MX2019013537A
Other languages
English (en)
Other versions
MX2019013537A (es
Inventor
Eliezer Zomer
Joseph M Johnson
Peter G Traber
Raphael Nir
Ryan George
Sharon Shechter
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of MX2019013537A publication Critical patent/MX2019013537A/es
Publication of MX392945B publication Critical patent/MX392945B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Algunos aspectos de la invención se relacionan con compuestos sintéticos novedosos que tienen afinidad de enlace con las proteínas de galectina.
MX2019013537A 2017-05-12 2018-05-11 Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. MX392945B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (2)

Publication Number Publication Date
MX2019013537A MX2019013537A (es) 2020-02-13
MX392945B true MX392945B (es) 2025-03-19

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013537A MX392945B (es) 2017-05-12 2018-05-11 Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.

Country Status (12)

Country Link
US (2) US11576924B2 (es)
EP (1) EP3621973A4 (es)
JP (1) JP7204676B2 (es)
KR (1) KR102626669B1 (es)
CN (1) CN110869378B (es)
AU (1) AU2018265571B2 (es)
BR (1) BR112019023722A2 (es)
CA (1) CA3062648A1 (es)
IL (1) IL270469B2 (es)
MX (1) MX392945B (es)
WO (1) WO2018209255A1 (es)
ZA (1) ZA201908165B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511094A (ja) 2018-12-06 2022-01-28 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
BR112021012482A2 (pt) * 2018-12-27 2021-09-08 Glycomimetics, Inc. C-glicosídeos inibidores de galectina-3
JP7478165B2 (ja) * 2019-03-26 2024-05-02 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
KR102854071B1 (ko) 2019-08-09 2025-09-02 이도르시아 파마슈티컬스 리미티드 (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체
BR112021026829A2 (pt) 2019-08-15 2022-02-22 Idorsia Pharmaceuticals Ltd Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos; doenças e distúrbios hepáticos; doenças e distúrbios cardiovasculares; doenças proliferativas celulares e cânceres; doenças e distúrbios inflamatórios e autoimunes; doenças e distúrbios do trato gastrointestinal; doenças e distúrbios pancreáticos; doenças e distúrbios associados à angiogênese anormal; doenças e distúrbios associados ao cérebro; dor neuropática e neuropatia periférica; doenças e distúrbios oculares; lesão renal aguda e doença renal crônica; doenças e distúrbios pulmonares intersticiais; ou rejeição ao transplante
KR102824799B1 (ko) 2019-08-29 2025-06-24 이도르시아 파마슈티컬스 리미티드 알파-d-갈락토피라노시드 유도체
CA3161794A1 (en) * 2019-12-24 2021-07-01 John L. Magnani Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols
WO2021226002A1 (en) 2020-05-05 2021-11-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2021231243A1 (en) 2020-05-11 2021-11-18 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR20230018431A (ko) 2020-05-28 2023-02-07 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3 억제제
MX2023004033A (es) 2020-10-06 2023-04-27 Idorsia Pharmaceuticals Ltd Espiro derivados de alfa-d-galactopiranosidos.
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
ES3032987T3 (en) * 2021-02-09 2025-07-29 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
US20240109930A1 (en) * 2021-03-03 2024-04-04 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9626450D0 (en) * 1996-12-20 1997-02-05 Oxford Glycosciences Uk Ltd Therapeutic compounds
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
GB0501008D0 (en) 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
EP2297174B1 (en) 2008-05-16 2015-07-08 Galecto Biotech AB Novel synthesis of galactoside inhibitors
EP2424873B1 (en) 2009-04-28 2017-11-15 Galecto Biotech AB Novel galactoside inhibitors of galectins
US8672857B2 (en) 2009-08-25 2014-03-18 Bg Medicine, Inc. Galectin-3 and cardiac resynchronization therapy
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
ES2869884T3 (es) 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
JP6133894B2 (ja) 2011-12-28 2017-05-24 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ヒト疾患処置用の新規糖薬剤の組成物
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
CN104822382B9 (zh) 2012-10-10 2019-01-18 卡莱克汀医疗有限公司 用于治疗糖尿病性肾病和相关疾病的半乳糖分支的糖类化合物
IN2015DN02573A (es) * 2012-10-31 2015-09-11 Galecto Biotech Ab
CN104955471A (zh) 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
CA2942320A1 (en) 2014-03-10 2015-09-17 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders
EP3129032A1 (en) 2014-04-08 2017-02-15 Galecto Biotech AB Galactoside inhibitors for the treatment of alpha-synucleinopthies
US10253059B2 (en) 2014-07-09 2019-04-09 Galecto Biotech Ab Hybrid galactoside inhibitor of galectins
CN113621005B (zh) * 2015-01-30 2025-07-04 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
WO2017019770A1 (en) 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
CN108602848B (zh) 2015-11-09 2022-01-18 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
WO2017152048A1 (en) 2016-03-04 2017-09-08 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
EP3621975A1 (en) 2017-05-12 2020-03-18 Galectin Sciences, LLC Compounds for the treatment of systemic insulin resistance disorders and the use thereof

Also Published As

Publication number Publication date
IL270469A (es) 2019-12-31
US11576924B2 (en) 2023-02-14
KR102626669B1 (ko) 2024-01-17
EP3621973A1 (en) 2020-03-18
IL270469B1 (en) 2023-03-01
KR20200016246A (ko) 2020-02-14
WO2018209255A1 (en) 2018-11-15
JP2020519625A (ja) 2020-07-02
JP7204676B2 (ja) 2023-01-16
US20200155586A1 (en) 2020-05-21
ZA201908165B (en) 2023-07-26
EP3621973A4 (en) 2021-10-27
CN110869378A (zh) 2020-03-06
AU2018265571B2 (en) 2022-09-29
IL270469B2 (en) 2023-07-01
CN110869378B (zh) 2023-10-13
CA3062648A1 (en) 2018-11-15
US20230132265A1 (en) 2023-04-27
BR112019023722A2 (pt) 2020-05-26
MX2019013537A (es) 2020-02-13
AU2018265571A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX392945B (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
MX394409B (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
MX2018003491A (es) Represores de htt y usos de estos.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
PE20170256A1 (es) Proteinas de union y sus metodos de uso
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
EA201891299A1 (ru) Терапевтические антитела к cd9
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2019003557A1 (es) Anticuerpos anti-trkb.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades